September 15, 2021
Robert Tessarolo has 25 years’ experience in the pharmaceutical industry, holding Chief Executive roles over two decades. Prior to his
September 8, 2021
Tryp Therapeutics stands apart from its peers by focusing on nociplastic pain, with the vast majority of companies exploring psychedelic
September 1, 2021
In 2019, RYAH Group pivoted towards becoming an Internet of Things (IoT) device platform, and as a result of the
August 25, 2021
Companies and investors are turning their attention to virtual and augmented reality technology, to enhance the impact and accessibility of
August 22, 2021
Beckley Psytech announced the completion of its oversubscribed Series B funding round, with US$80 million raised to develop psilocybin and
August 22, 2021
Last summer four Canadians received exemptions from the Controlled Drugs and Substances Act, to harness psilocybin in psychotherapy. Since the
August 4, 2021
To date, HMNC Brain Health has raised €28m in funding for the continued development of precision psychiatry. Precision psychiatry is a methodology that
July 27, 2021
Field Trip will join the Nasdaq exchange on 29 July and become the first psychedelic company to list on Nasdaq’s
July 22, 2021
COVID-19 and the ‘new normal’ for healthcare provision Pioneers and early movers in the psychedelics industry are using tech to
July 20, 2021
At the start of July, US President Joe Biden signed an executive order to drive down prescription drug prices, with
July 14, 2021
Big data has revolutionised healthcare, enhancing treatment safety, efficacy and operational efficiency. The technology has become crucial to accelerate drug
July 12, 2021
The industry-leading global event series returned on 7 July, with the PSYCH Investor Summit: Research & Development delivering investor-focused panel
